A phase II trial shows that pembrolizumab and bevacizumab yield a 54.1% intracranial response rate and a median overall ...
THE GLOBAL prevalence of Parkinson’s disease is projected to more than double by 2050, reaching 25.2 million cases, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback